Sp903
UNDERSTANDING AND MANAGING FUNCTIONAL AND INFLAMMATORY PROBLEMS OF THE POUCH
Date
May 8, 2023
Explore related products in the following collection:
Society: AGA
Management of diseases of the ileo-anal pouch and perianal Crohn’s disease is challenging and involves multidisciplinary medical and surgical care. This session review the contemporary management of these complex clinical situations. It will also update the clinician and researcher on the emerging concepts of fibrosis as a therapeutic target as well as aging and frailty in in the management of IBD.
Management of diseases of the ileo-anal pouch and perianal Crohn’s disease is challenging and involves multidisciplinary medical and surgical care. This session review the contemporary management of these complex clinical situations. It will also update the clinician and researcher on the emerging concepts of fibrosis as a therapeutic target as well as aging and frailty in in the management of IBD.
Presenter
Icahn School of Medicine Mount Sinai Hospital
Tracks
Related Products
PLACEHOLDER
Perturbations in the gut mucosal immune response contributes to IBD. Non-immune cell popopulations including epithelial and stromal cells also play an important role in intestinal inflammation…
ENCAPSULATED MICROBIOTA TRANSPLANT THERAPY IMPROVES PARTIAL MAYO SCORES IN ULCERATIVE COLITIS AND INDUCES RAPID ENGRAFTMENT COMPARED TO PLACEBO CONTROL
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
PANEL DISCUSSION
Management of diseases of the ileo-anal pouch and perianal Crohn’s disease is challenging and involves multidisciplinary medical and surgical care. This session review the contemporary management of these complex clinical situations…
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
